Please wait while the formulary information is being retrieved.
CABLIVI (caplacizumab-yhdp)
- Acquired thrombotic thrombocytopenic purpura
11 mg solution for injection
- Inject 11 mg by subcutaneous route once daily in the abdomen for 30 days beyond the last plasma exchange
11 mg injection kit
- Inject 11 mg by subcutaneous route once daily in the abdomen for 30 days beyond the last plasma exchange
Acquired thrombotic thrombocytopenic purpura
- Inject 11 mg by intravenous route once as an iv bolus at least 15 minutes prior to plasma exchange
- Inject 11 mg by subcutaneous route once after completion of plasma exchange
- Inject 11 mg by subcutaneous route once daily in the abdomen for 30 days beyond the last plasma exchange
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Increased risk of bleeding
Severe
Moderate
- None
CABLIVI (caplacizumab-yhdp)
- Acquired thrombotic thrombocytopenic purpura
- None
- Epistaxis
- Gingival bleeding
- Headache disorder
More Frequent
Severe
Less Severe
- Hypersensitivity drug reaction
- Menorrhagia
- Rectal bleeding
- Upper GI bleed
- Abnormal vaginal bleeding
- Back pain
- Dyspnea
- Fatigue
- Fever
- Hematuria
- Injection site sequelae
- Myalgias
- Paresthesia
- Urinary tract infection
- Urticaria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hematoma of abdominal wall
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Caplacizumab-yhdp
Safety and effectiveness in pediatric patients have not been established.
- 1 Day – 18 Years
- Safety and effectiveness in pediatric patients have not been established.
Caplacizumab-yhdp
- Severity Level:
2
- Additional Notes: Insufficient human data available. monitor neonates for bleeding.
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Caplacizumab-yhdp
None
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Acquired thrombotic thrombocytopenic purpura | |
M31.1 | Thrombotic microangiopathy |
0-9 | A-Z |
---|---|
M31.1 | Thrombotic microangiopathy |
Formulary Reference Tool